Cargando…

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study

BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ming-Han, Kao, Tzu-Yu, Hsieh, Ting-Hui, Kao, Chun-Chi, Peng, Cheng-Yuan, Lai, Hsueh-Chou, Chuang, Po-Heng, Kao, Jung-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771741/
https://www.ncbi.nlm.nih.gov/pubmed/35070254
http://dx.doi.org/10.1177/20406223211067631
_version_ 1784635679066554368
author Hsieh, Ming-Han
Kao, Tzu-Yu
Hsieh, Ting-Hui
Kao, Chun-Chi
Peng, Cheng-Yuan
Lai, Hsueh-Chou
Chuang, Po-Heng
Kao, Jung-Ta
author_facet Hsieh, Ming-Han
Kao, Tzu-Yu
Hsieh, Ting-Hui
Kao, Chun-Chi
Peng, Cheng-Yuan
Lai, Hsueh-Chou
Chuang, Po-Heng
Kao, Jung-Ta
author_sort Hsieh, Ming-Han
collection PubMed
description BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). RESULTS: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) (n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases (n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort (n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases (n = 59) was significantly higher than that in non-SVR cases (n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. CONCLUSIONS: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.
format Online
Article
Text
id pubmed-8771741
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87717412022-01-21 Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study Hsieh, Ming-Han Kao, Tzu-Yu Hsieh, Ting-Hui Kao, Chun-Chi Peng, Cheng-Yuan Lai, Hsueh-Chou Chuang, Po-Heng Kao, Jung-Ta Ther Adv Chronic Dis Original Research BACKGROUND: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. METHODS: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). RESULTS: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) (n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases (n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort (n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases (n = 59) was significantly higher than that in non-SVR cases (n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. CONCLUSIONS: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment. SAGE Publications 2022-01-13 /pmc/articles/PMC8771741/ /pubmed/35070254 http://dx.doi.org/10.1177/20406223211067631 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Hsieh, Ming-Han
Kao, Tzu-Yu
Hsieh, Ting-Hui
Kao, Chun-Chi
Peng, Cheng-Yuan
Lai, Hsueh-Chou
Chuang, Po-Heng
Kao, Jung-Ta
Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title_full Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title_fullStr Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title_full_unstemmed Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title_short Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
title_sort long-term surveillance of liver histological changes in chronic hepatitis c patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771741/
https://www.ncbi.nlm.nih.gov/pubmed/35070254
http://dx.doi.org/10.1177/20406223211067631
work_keys_str_mv AT hsiehminghan longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT kaotzuyu longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT hsiehtinghui longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT kaochunchi longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT pengchengyuan longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT laihsuehchou longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT chuangpoheng longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy
AT kaojungta longtermsurveillanceofliverhistologicalchangesinchronichepatitiscpatientscompletingpegylatedinterferonaplusribavirintherapyanobservationalcohortstudy